Path: mechanisms/vps35-pathway-parkinsons Title: VPS35 Pathway in Parkinson's Disease Tags: section:mechanisms, kind:pathology, topic:parkinson, topic:retromer, topic:endosomal-sorting, topic:protein-trafficking, topic:genetics
VPS35 (Vacuolar Protein Sorting 35) is a core component of the retromer complex, a multisubunit assembly that mediates retrograde transport of proteins from endosomes to the trans-Golgi network (TGN) or the plasma membrane[@belenkaya2008]. The retromer plays a critical role in endosomal protein sorting, and VPS35 dysfunction has emerged as a significant contributor to neurodegenerative processes, particularly in Parkinson's disease (PD)[@zhang2020]. Heterozygous VPS35 mutations (e.g., p.D620N) cause autosomal dominant familial PD, while subtle VPS35 dysfunction may contribute to sporadic disease pathogenesis[@vilaj2013].
The retromer complex coordinates the retrieval of cargo proteins from endosomes, a process essential for maintaining cellular protein homeostasis. In neurons, retromer function is particularly critical due to the elaborate membrane trafficking required for synaptic vesicle recycling, neurotransmitter receptor trafficking, and axonal transport[@mcfriendly2012]. VPS35 mutations impair retromer function, leading to disrupted sorting of proteins critical for neuronal survival, including [alpha-synuclein](/proteins/alpha-synuclein), [LRRK2](/genes/lrrk2), and neurotransmitter receptors[@dawson2010].
Path: mechanisms/vps35-pathway-parkinsons Title: VPS35 Pathway in Parkinson's Disease Tags: section:mechanisms, kind:pathology, topic:parkinson, topic:retromer, topic:endosomal-sorting, topic:protein-trafficking, topic:genetics
VPS35 (Vacuolar Protein Sorting 35) is a core component of the retromer complex, a multisubunit assembly that mediates retrograde transport of proteins from endosomes to the trans-Golgi network (TGN) or the plasma membrane[@belenkaya2008]. The retromer plays a critical role in endosomal protein sorting, and VPS35 dysfunction has emerged as a significant contributor to neurodegenerative processes, particularly in Parkinson's disease (PD)[@zhang2020]. Heterozygous VPS35 mutations (e.g., p.D620N) cause autosomal dominant familial PD, while subtle VPS35 dysfunction may contribute to sporadic disease pathogenesis[@vilaj2013].
The retromer complex coordinates the retrieval of cargo proteins from endosomes, a process essential for maintaining cellular protein homeostasis. In neurons, retromer function is particularly critical due to the elaborate membrane trafficking required for synaptic vesicle recycling, neurotransmitter receptor trafficking, and axonal transport[@mcfriendly2012]. VPS35 mutations impair retromer function, leading to disrupted sorting of proteins critical for neuronal survival, including [alpha-synuclein](/proteins/alpha-synuclein), [LRRK2](/genes/lrrk2), and neurotransmitter receptors[@dawson2010].
VPS35 is a 796-amino acid protein that serves as the core scaffold of the retromer complex:
N-terminal domain: The N-terminal portion of VPS35 interacts with VPS26 (VPS26A or VPS26B) to form a cargo recognition module that binds to sorting motifs on target proteins[@shi2009].
C-terminal domain: The C-terminal region interacts with VPS29 and contributes to membrane association through interactions with the WASH complex[@hierro2010].
D620N mutation: The most common disease-causing VPS35 mutation (p.D620N) is located in the C-terminal domain and impairs interactions with VPS29 and the WASH complex, reducing retromer stability[@mcgough2014].
The retromer consists of a cargo recognition complex and a membrane deformation subunit:
Cargo recognition complex (CRC):
The retromer executes several critical sorting functions:
Familial PD mutations: The VPS35 p.D620N mutation was first identified in 2013 as a cause of autosomal dominant familial Parkinson's disease[@vilaj2013a]. This mutation shows near-complete penetrance with typical PD onset between 50-65 years.
Mutation frequency: VPS35 mutations account for approximately 1-2% of familial PD cases, making it one of the more common genetic causes of PD[@foo2020].
Sporadic PD: Studies suggest reduced VPS35 expression and retromer dysfunction may contribute to sporadic PD pathogenesis through mechanisms distinct from the D620N mutation[@steger2016].
VPS35 dysfunction contributes to PD through multiple interconnected mechanisms:
Alpha-synuclein metabolism: The retromer regulates trafficking of alpha-synuclein and its sorting receptors. VPS35 dysfunction leads to increased alpha-synuclein aggregation through impaired lysosomal targeting and altered secretory pathways[@dawson2010a]. Studies show retromer components colocalize with Lewy bodies in PD brains[@tang2015].
LRRK2 regulation: LRRK2 (leucine-rich repeat kinase 2), another PD-associated protein, is regulated by retromer-mediated trafficking. VPS35 dysfunction can alter LRRK2 subcellular localization and function[@steger2017].
Dopamine transporter trafficking: The dopamine transporter (DAT) requires retromer function for proper synaptic terminal localization. VPS35 impairment leads to altered dopamine homeostasis[@cai2019].
Mitochondrial quality control: Retromer function intersects with mitochondrial dynamics and mitophagy. VPS35 mutations may impair PINK1/Parkin-mediated mitophagy, contributing to dopaminergic neuron vulnerability[@sanchez2021].
Synaptic vesicle recycling: The retromer is essential for synaptic vesicle protein trafficking. Impaired retromer function disrupts synaptic vesicle pools and neurotransmitter release[@mcfriendly2012a].
Receptor trafficking: NMDA and AMPA glutamate receptors require retromer-mediated sorting. VPS35 dysfunction contributes to excitotoxicity through altered receptor trafficking[@kerr2015].
Axonal transport: Endosomal trafficking is critical for axonal maintenance. Retromer impairment disrupts axonal transport and contributes to neurodegeneration[@fu2019].
The retromer sits at the intersection of endosomal trafficking and lysosomal degradation:
Endosomal maturation: Retromer function is intertwined with endosomal maturation. Dysfunction leads to accumulation of enlarged endosomes and impaired cargo delivery[@hu2021].
Lysosomal targeting: The retromer directs proteins toward lysosomal degradation or retrieval. Impaired function leads to aberrant protein accumulation[@rong2018].
Autophagy: Retromer intersects with autophagy pathways. VPS35 dysfunction disrupts autophagic flux and leads to protein aggregate accumulation[@gong2019].
Retromer dysfunction contributes to neuroinflammation through:
Glial activation: Impaired neuronal protein trafficking leads to release of DAMPs that activate microglia[@henkel2012].
Cytokine production: Neuronal stress from retromer dysfunction triggers inflammatory cytokine production[@zhang2018].
Neurovascular unit: The retromer affects endothelial cell function and blood-brain barrier integrity[@zlokovic2011].
ER stress: Retromer dysfunction causes ER stress through accumulation of misfolded proteins[@wang2019].
Proteostasis failure: Impaired lysosomal targeting leads to proteostasis network collapse[@klauck2020].
Aggregate formation: Alpha-synuclein and other proteins form toxic aggregates when retromer-mediated clearance is impaired[@xilouri2016].
Retromer stabilizers: Small molecules that stabilize the retromer complex are in development. These compounds enhance VPS35-VPS29 interactions and improve retromer assembly[@mcgough2017a].
Protein-protein interaction inhibitors: Inhibiting proteins that compete with retromer for cargo binding can enhance retromer function[@zhang2020a].
Gene therapy: VPS35 gene delivery to restore retromer function is being explored in preclinical models[@sanchez2021a].
Alpha-synuclein reduction: Reducing alpha-synuclein expression or enhancing its clearance can compensate for retromer dysfunction[@kluge2018].
Lysosomal enhancement: Enhancing lysosomal function can compensate for impaired retromer-mediated trafficking to lysosomes[@barton2020].
Neuroprotection: Antioxidants and anti-inflammatory agents may protect neurons from retromer dysfunction-induced injury[@chen2019].
| Compound | Mechanism | Stage | Company |
|----------|------------|-------|---------|
| R55 | Retromer stabilizer | Preclinical | None identified |
| Antisense oligonucleotides | VPS35 upregulation | Preclinical | Various |
| Gene therapy | VPS35 delivery | Preclinical | Research |
VPS35 D620N knock-in: Mouse models carrying the VPS35 D620N mutation show age-dependent motor deficits and alpha-synuclein pathology[@steger2016a].
Conditional knockout: Tissue-specific VPS35 knockout mice develop neurodegeneration and alpha-synuclein aggregation[@tang2015a].
VPS35 haploinsufficiency: Heterozygous VPS35 mice show intermediate phenotypes, suggesting dose-sensitivity[@mcfriendly2014].
Zebrafish provide accessible models for studying VPS35 function:
Morpholino knockdown: VPS35 knockdown disrupts dopaminergic neuron development[@fisch2015].
Transgenic models: Zebrafish expressing mutant VPS35 show relevant phenotypes for drug screening[@zhang2018a].
Western blotting: Measuring VPS35 levels and retromer complex assembly[@crotts2016a].
Immunoprecipitation: Assessing VPS35-VPS29 interactions[@hierro2010a].
Subcellular fractionation: Localizing retromer components to endosomal fractions[@gao2017].
Live-cell imaging: Monitoring cargo trafficking in real-time[@mcfriendly2018].
GWAS: Genome-wide association studies have identified VPS35 variants associated with PD risk[@nalls2019].
Sequencing: Next-generation sequencing of VPS35 in PD patients[@foo2020a].
Expression analysis: Transcriptomic and proteomic studies of VPS35 in PD brains[@steger2016b].
LRRK2: The retromer regulates LRRK2 trafficking and is regulated by LRRK2 phosphorylation[@steger2017a].
PINK1/Parkin: Retromer function intersects with mitophagy pathways[@sanchez2021b].
GBA: Glucocerebrosidase and retromer both affect lysosomal function[@sidransky2019].
Alzheimer's disease: Retromer dysfunction affects APP trafficking and amyloid production[@zhang2015].
Huntington's disease: Retromer regulates huntingtin trafficking[@kayatekin2018].
ALS: Retromer affects TDP-43 and SOD1 trafficking[@fecto2021].
The VPS35 pathway represents a critical mechanism in Parkinson's disease pathogenesis:
Genetic testing for VPS35 mutations is recommended for individuals with early-onset Parkinson's disease (under 60 years) with a family history consistent with autosomal dominant inheritance. The D620N mutation shows incomplete penetrance, with some carriers remaining asymptomatic into late adulthood. Comprehensive genetic panels for PD-associated genes are widely available and can detect both known and novel VPS35 variants. Pathogenic variants require careful interpretation, and variants of uncertain significance present challenges for genetic counseling[@gaig2014].
Studies are evaluating retromer protein levels in cerebrospinal fluid (CSF) as potential biomarkers, with reduced VPS35 levels potentially indicating retromer dysfunction. CSF alpha-synuclein species, particularly oligomeric forms, may be elevated in patients with VPS35-related PD. Neurofilament light chain (NfL) serves as a general marker of neurodegeneration and may help stage disease severity[@steger2016c].
Motor symptoms in VPS35-PD are similar to typical sporadic PD, including resting tremor (classic pill-rolling pattern), bradykinesia, rigidity (cogwheel or lead-pipe), and postural instability developing over 5-10 years. Non-motor symptoms include hyposmia (early feature), REM sleep behavior disorder, constipation, cognitive impairment, and psychiatric symptoms (depression, anxiety, psychosis with dopaminergic therapy)[@jankovic2014].
Levodopa (carbidopa/levodopa combinations) remains first-line for motor symptoms. Dopamine agonists (pramipexole, ropinirole) and MAO-B inhibitors (selegiline, rasagiline) provide symptom control. Deep brain stimulation (VIM or GPi) effectively reduces motor symptoms in appropriately selected patients. Non-pharmacological approaches including regular exercise, physical therapy, and speech therapy are essential[@fahn2015].
VPS35 dysfunction particularly affects dopaminergic neurons in the substantia nigra pars compacta due to several factors. These neurons have high metabolic demands and rely heavily on efficient protein trafficking for synaptic function, neurotransmitter synthesis, and axonal maintenance. The retromer-mediated retrieval of proteins from endosomes is essential for preserving synaptic vesicle pools and dopamine transporter function. When VPS35 function is impaired, these critical processes become dysregulated, leading to progressive dopaminergic neuron loss[@cai2019].
The substantia nigra neurons also have unique iron metabolism requirements, and retromer dysfunction may impair iron handling proteins, contributing to oxidative stress. Additionally, these neurons have extensive axonal arborizations requiring efficient axonal transport, which is compromised by endosomal trafficking defects[@sanchez2021].
The retromer plays a critical role in synaptic function through multiple mechanisms. Synaptic vesicle proteins require constant recycling through the endosomal system, and retromer impairment disrupts this process. This leads to depletion of synaptic vesicle pools, impaired neurotransmitter release, and eventual synaptic degeneration. Studies in VPS35 mutant models show reduced synaptic vesicle numbers and altered release kinetics[@mcfriendly2012a].
Postsynaptic glutamate receptors (NMDA and AMPA) also require retromer-mediated trafficking for proper synaptic localization. VPS35 dysfunction leads to altered receptor composition at synapses, contributing to excitotoxicity. The dysregulation of synaptic proteins may be an early event in neurodegeneration, preceding cell body death[@kerr2015].
The retromer intersects with mitochondrial quality control pathways in several ways. Retromer function is required for proper trafficking of proteins involved in mitochondrial dynamics (fusion, fission) and mitophagy receptors. VPS35 mutations impair PINK1/Parkin-mediated mitophagy, leading to accumulation of dysfunctional mitochondria. This is particularly relevant given the high energy demands of dopaminergic neurons and their susceptibility to oxidative stress[@fu2019].
Additionally, the retromer affects mitochondrial trafficking within neurons. Proper distribution of mitochondria along axons is essential for neuronal survival, and retromer dysfunction disrupts mitochondrial transport, creating energy deficits in distal axon segments[@hu2021].
Induced neurons: Patient-derived induced pluripotent stem cells (iPSCs) can be differentiated into dopaminergic neurons, providing relevant disease models. These cells show altered retromer function, impaired alpha-synuclein handling, and increased vulnerability to stressors[@rong2018].
Knockdown models: siRNA-mediated VPS35 knockdown in neuronal cell lines reveals the consequences of retromer dysfunction for protein trafficking and cell survival. These models show accumulation of alpha-synuclein and impaired lysosomal function[@gong2019].
CRISPR models: CRISPR-Cas9 editing enables precise introduction of the D620N mutation or other variants, providing isogenic lines for studying mutation-specific effects[@henkel2012].
Mouse models: Transgenic mice expressing human VPS35 D620N show age-dependent motor deficits, alpha-synuclein pathology, and dopaminergic neuron loss. These models recapitulate key features of human PD and enable therapeutic testing[@zhang2018].
Zebrafish: Zebrafish models offer advantages for drug screening due to their rapid development and transparency. VPS35 morphant zebrafish show disrupted dopaminergic neuron development[@zlokovic2011].
C. elegans: Simple invertebrate models enable study of conserved retromer functions and genetic modifiers. Worm models have identified pathways that modify VPS35-related neurodegeneration[@wang2019].
High-throughput screening: Cell-based assays measuring retromer function (cargo trafficking, protein sorting) enable screening of compound libraries for retromer-enhancing activity. These screens have identified candidate compounds being optimized for clinical use[@klauck2020].
Organoid models: Brain organoids derived from patient iPSCs provide three-dimensional models that capture some aspects of neuronal circuitry and cell-cell interactions relevant to retromer biology[@xilouri2016].
Retromer stabilizers: The development of small molecules that stabilize the retromer complex represents a promising approach. These compounds enhance the VPS35-VPS29 interaction and improve retromer assembly and function. Lead compounds have shown efficacy in cellular and mouse models[@mcgough2017a].
Kinase inhibitors: Several kinases involved in retromer regulation (including LRRK2) are targets for PD therapy. LRRK2 inhibitors are in clinical development and may benefit patients with VPS35-related PD[@zhang2020a].
Autophagy enhancers: Compounds that enhance autophagy (including mTOR inhibitors and autophagy-inducing peptides) may compensate for impaired lysosomal targeting by promoting alternative clearance pathways[@sanchez2021a].
Gene therapy: AAV-mediated VPS35 delivery to the brain aims to restore retromer function. This approach faces challenges including achieving adequate transduction and expression levels in affected neurons[@kluge2018].
Antisense oligonucleotides: ASOs targeting alpha-synuclein or other toxic proteins may benefit patients with VPS35-related PD by reducing the burden of proteins that accumulate with impaired retromer function[@barton2020].
Protein replacement: Recombinant protein delivery faces challenges due to the need for intracellular delivery to neurons[@chen2019].
Several existing drugs may have beneficial effects in VPS35-related PD:
Statins: Some epidemiological studies suggest statins may reduce PD risk, potentially through effects on protein trafficking[@steger2016a].
Metformin: This diabetes drug affects cellular metabolism and autophagy; retrospective studies suggest possible PD risk reduction[@tang2015a].
NSAIDs: Anti-inflammatory drugs may provide neuroprotection by reducing neuroinflammation that exacerbates retromer dysfunction[@mcfriendly2014].
[^27
[@mcgough2017a]